Treatment of symptomatic polyneuropathy with actovegin in type 2 diabetic patients
about
Treating Diabetic Neuropathy: Present Strategies and Emerging Solutions.Recurrent hamstring muscle injury: applying the limited evidence in the professional football setting with a seven-point programmeDiabetes and the brain: issues and unmet needs.Actovegin®: a biological drug for more than 5 decades.Burning through the pain: treatments for diabetic neuropathy.Small organic molecule disruptors of Cav3.2 - USP5 interactions reverse inflammatory and neuropathic pain.Hemoglobin A1c improvements and better diabetes-specific quality of life among participants completing diabetes self-management programs: a nested cohort studyDiabetic neuropathy: mechanisms, emerging treatments, and subtypes.A Randomised, Double-Blind, Placebo-Controlled Trial of Actovegin in Patients with Post-Stroke Cognitive Impairment: ARTEMIDA Study Design.Diabetic neuropathy: cellular mechanisms as therapeutic targets.Whither pathogenetic treatments for diabetic polyneuropathy?Painful and painless diabetic neuropathy: one disease or two?Drugs for the treatment of peripheral neuropathies.Declining Skeletal Muscle Function in Diabetic Peripheral Neuropathy.Emerging drugs for diabetic peripheral neuropathy and neuropathic pain.Neuroprotective and anti-oxidative effects of the hemodialysate actovegin on primary rat neurons in vitro.Treatment with Actovegin improves spatial learning and memory in rats following transient forebrain ischaemia.Actovegin, a non-prohibited drug increases oxidative capacity in human skeletal muscle.
P2860
Q33583006-DC619A56-E64D-43E1-9ED9-142004855A33Q33659614-54A9326B-1176-4C3C-A5DC-6D5F474C6048Q33780337-DD2AFCEE-65B2-4B42-8B76-1075A767D2FFQ34170797-4B30D86B-AD29-4FB2-98E7-0C8915E1FCBEQ34485306-D7A92313-2230-4113-96D9-0207A54BD0A4Q35189552-2753E91D-38AB-403C-A045-C94608429A0FQ36143438-ED14B64A-78B7-46B4-8419-FA931497198EQ37375109-8AD6D838-02DE-4F26-A080-C9BADFCA0376Q37573625-72BD7BA4-0F94-4018-8B4A-7D7198AA09E0Q37930962-393681D8-2539-4920-BA5F-88C7FB83D760Q38079186-7A3A2CED-0D20-4CB0-AC7E-538BC9EE810DQ38107138-AD693B58-4A72-4F71-AF39-949E5547F274Q38633190-21CF7A2F-61EE-4682-B982-44AA33B60F36Q38676080-2872E91B-4EF2-483C-BB96-D35D3A03BB8CQ38798588-F7F40DA0-0924-4D93-BBC8-F3F0F513C711Q39253855-0C06D691-9EFA-4091-A8F8-8E8D0C02EC42Q41819831-F27960B8-39A2-453D-8925-929549FD46FCQ51557959-E181CCAF-D3F9-4946-A3FB-A8110425A04D
P2860
Treatment of symptomatic polyneuropathy with actovegin in type 2 diabetic patients
description
2009 nî lūn-bûn
@nan
2009 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Treatment of symptomatic polyneuropathy with actovegin in type 2 diabetic patients
@ast
Treatment of symptomatic polyneuropathy with actovegin in type 2 diabetic patients
@en
Treatment of symptomatic polyneuropathy with actovegin in type 2 diabetic patients
@nl
type
label
Treatment of symptomatic polyneuropathy with actovegin in type 2 diabetic patients
@ast
Treatment of symptomatic polyneuropathy with actovegin in type 2 diabetic patients
@en
Treatment of symptomatic polyneuropathy with actovegin in type 2 diabetic patients
@nl
prefLabel
Treatment of symptomatic polyneuropathy with actovegin in type 2 diabetic patients
@ast
Treatment of symptomatic polyneuropathy with actovegin in type 2 diabetic patients
@en
Treatment of symptomatic polyneuropathy with actovegin in type 2 diabetic patients
@nl
P2093
P2860
P356
P1433
P1476
Treatment of symptomatic polyneuropathy with actovegin in type 2 diabetic patients
@en
P2093
Boris Mankovsky
Dan Ziegler
Igor Strokov
Irina Gurieva
Lusine Movsesyan
Zhangentkhan Abylaiuly
P2860
P304
P356
10.2337/DC09-0545
P407
P577
2009-08-01T00:00:00Z